Navigation Links
Particle Sciences Expands Biopharmaceutical Development Infrastructure
Date:7/15/2014

BETHLEHEM, Pa., July 15, 2014 /PRNewswire/ -- Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis.  According to Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property.  We regularly work with biopharmaceuticals and vaccines ranging from therapeutic proteins, including monoclonal antibodies, to nucleotides, to vaccine antigens and immunomodulators.  Adding cell culture and extensive instrumentation to support the testing and characterizations of these biopharmaceuticals was planned for later this year but we've accelerated implementation to meet our client's needs."   With this most recent expansion, Particle Sciences can now run the full gambit of testing including, among others, ELISA, SDS-PAGE, Western blots, image analysis, HPLC, HPLC-MS, ligand-receptor binding assays, cellular proliferation, cytotoxicity and cellular activation assays.   

Mark Mitchnick, Particle Sciences' CEO added, "This expansion augments our existing formulation and sterile manufacturing offerings.  With our unique approach to biopharmaceutical formulation and the ability to quickly take our clients into the clinic, Particle Sciences anticipates becoming a leader in large molecule formulation and clinical trial supply."  The company sees a rapidly growing industrial need for these services as biopharmaceutical and biosimilar products become an increasingly important component to the health care products market. Particle Sciences' formulation portfolio enables the broader, more efficient development and application of biopharmaceuticals, and can differentiate products in the biosimilars field.

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  We also have an extensive history in government contracting alongside our clients.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com,  email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Contact: Maureen Grieco
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shimadzu Introduces New Particle Size Analyzer for Measurement of Nanoparticles in Life Sciences and R&D
2. New magnetic behavior in nanoparticles could lead to even smaller digital memories
3. DNA motor walks along nanotube, transports tiny particle
4. Nanoparticles and their orbital positions
5. Researchers split water into hydrogen, oxygen using light, nanoparticles
6. IceCube Particle Detector in Antarctica Records High-energy Neutrinos
7. Scientists develop way to successfully give nanoparticle therapeutics orally
8. Pills of the future: Nanoparticles
9. Ultra-sensitive force sensing with a levitating nanoparticle
10. Magnetic nanoparticles could aid heat dissipation
11. BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
(Date:1/23/2017)...  Spherix Incorporated (Nasdaq: SPEX ) an ... technology and monetization of intellectual property, today provided an ... Anthony Hayes , Chief Executive Officer of Spherix, ... communicate with shareholders about the status of existing monetization ... other patent assets that fit with our current holdings.  ...
(Date:1/23/2017)... PA (PRWEB) , ... January 23, 2017 , ... ... Thomas has been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. ... of Madras in India. , Dr. Thomas’ career as an academic and ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific ... healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices in ... scientific consultants and contractors. This is the latest step in G&L’s expansion of ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/16/2016)... NEW YORK , Dec. 16, 2016 The global ... reach USD 12.14 billion by 2021 from USD 5.31 billion in ... ... market is mainly driven by technological advancements in medical devices, launch ... devices, rising preference for wireless connectivity among healthcare providers, and increasing ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):